Dr Arthur Levinson joins board at NGM
This article was originally published in Scrip
Executive Summary
NGM Biopharmaceuticals, a private US company discovering and developing biotherapeutics for the treatment of type 2 diabetes and other metabolic diseases, has elected Dr Arthur Levinson to its board of directors. Dr Levinson is chairman of Genentech's board of directors, an advisor to Genentech's research and early development centre and a member of Roche's scientific resource board. He will also be nominated to Roche's board of directors in March 2010.